Grifols is anticipating a period of strong growth on the back of its recently FDA-approved intravenous immunoglobulin product Yimmugo ... has dropped the list of the next 15 drugs to be negotiated ...

Considering the popularity of plasma donation as a side hustle in the United States, I’ve decided to compile a list of the highest-paying centers ... including referral incentives for bringing in new ...

ADMA Biologics ADMA shares have skyrocketed 275.7% in a year against the industry’s decline of 14.3%. The stock has also ...

AbbVie may still have an edge, though, as ND-0612 requires two injection entry points compared to Produodopa’s one, and AbbVie’s product ... list price of £84.70 per vial ahead of discounts ...

This is the second volume of the Research Topic titled 'Novel Insights into CAR T-cell Associated Neurotoxicity'. You may ...

U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding ...

Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms ...

Initiative aims to identify plasma-based biomarkers for early detection Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF ...

Spanish pharma Grifols is leveraging its massive collection of plasma samples to look for early biomarkers of Parkinson’s disease (PD) thanks to a $21 million grant from the Michael J.

"We urge the CNMV to consider the benefits to all Grifols shareholders from improved disclosure," Mason Capital said. As global markets navigate a mixed economic landscape marked by declining ...